Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

In an investigator-sponsored trial at Memorial Sloan Kettering (MSK), 80% of SER-155 recipients achieved an immunosuppressive-free clinical response by day 15 for immune checkpoint inhibitor-related enterocolitis (irEC). The early efficacy read-through is a meaningful positive signal for the treatment profile in this setting, though it remains limited to an investigator-sponsored study.

Analysis

In an investigator-sponsored trial at Memorial Sloan Kettering (MSK), 80% of SER-155 recipients achieved an immunosuppressive-free clinical response by day 15 for immune checkpoint inhibitor-related enterocolitis (irEC). The early efficacy read-through is a meaningful positive signal for the treatment profile in this setting, though it remains limited to an investigator-sponsored study.